Aspire Biopharma Holdings, Inc. 8-K

What Happened

• Aspire Biopharma Holdings, Inc. reported in an 8-K (filed June 22, 2026) that at a Special Meeting on June 16, 2026 its stockholders approved three warrant-related proposals tied to a Warrant Agreement. The approvals authorize issuance of the common shares issuable upon exercise of the warrants (including issuance in excess of 19.99% of outstanding stock as measured on April 22, 2026) and permit adjustments to the number of shares and the exercise price under the warrants.
• The Warrant Agreement and related adjustments reference an agreement dated March 17, 2026 with the company’s financial advisor. The exercise price approved for the warrants is $0.00001 per share.

Key Details

• Vote results for the Warrant Issuance Proposal: For 1,742,683; Against 107,523; Abstain 4,818; Broker Non-Votes 0.
• Vote results for the Share Adjustment Proposal: For 1,745,709; Against 103,550; Abstain 5,764; Broker Non-Votes 0.
• Vote results for the Exercise Price Adjustment Proposal: For 1,739,702; Against 110,483; Abstain 4,839; Broker Non-Votes 0.
• Purpose includes compliance with Nasdaq listing rule 5635(d) on issuance of shares upon exercise.

Why It Matters

• These shareholder approvals permit the company to issue the shares tied to the warrants (including issuance above the 19.99% threshold) and to change the number of shares and exercise price as provided in the Warrant Agreement. For investors, this can affect future dilution and the potential number of outstanding shares if the warrants are exercised. The filing documents the formal shareholder consent and vote counts but does not report any immediate cash proceeds—exercise would depend on future warrant holders converting their warrants.